Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02849626 · ClinicalTrials.gov registry record · Phase 3
Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT02849626 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 180 participants.
The verdict
NCT02849626, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than \[\<\] 12 years) with inadequately controlled partial onset seizures (POS) or primary generalized tonic clonic (PGTC) seizures.
Interventions
- DRUG Perampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2016-11-16 |
| Est. Completion | 2021-12-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02849626
The ClinicalTrials.gov registry entry for NCT02849626 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perampanel is the first listed.
NCT02849626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02849626 about?
NCT02849626 is a clinical study titled "Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures". This is an open-label, multicenter study with an Extension Phase to evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to less than \[\<\] 12 years) with inadequately controlled partial onset seizures (POS) or primary gen...
What is the current status of trial NCT02849626?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2016-11-16. Estimated completion is 2021-12-06.
What interventions are being tested in trial NCT02849626?
The interventions under investigation include: Perampanel (DRUG).
Who is sponsoring clinical trial NCT02849626?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.